Clinical TrialMay 13, 2026, 06:02 AM
Voyager VY1706 Alzheimer's gene therapy shows positive GLP data; IND on track
AI Summary
Voyager Therapeutics announced positive 3-month GLP toxicology data for VY1706, its investigational tau silencing gene therapy for Alzheimer's disease, showing it was well tolerated and reduced tau protein up to 64% in non-human primates. The company's IND application process for VY1706 is on track for Q2 2026, with first-in-human dosing expected in H2 2026. Additionally, data from eight ASGCT presentations highlighted Voyager's continued innovation in gene therapy, including advancements in capsid discovery for muscular and neuromuscular targeting, immune evasion, and manufacturability.
Key Highlights
- VY1706 showed favorable tolerability with no adverse findings up to the highest dose tested (5E13 vg/kg).
- VY1706 reduced tau protein up to 64% in key brain regions of NHPs at 13 weeks.
- Voyager's VY1706 IND application process is on track for Q2 2026.
- First-in-human dosing for VY1706 in Alzheimer's patients is projected for H2 2026.
- Top muscle-targeted capsid achieved 100X increased expression over AAV9 in mice.
- Top muscle-targeted capsid achieved 25-30X increased expression over AAV9 in NHPs.
- A next-generation "stealth" capsid evaded pre-existing neutralizing antibodies while retaining muscle tropism.